| P50 | author | Renato Talamini | Q16122860 |
| | Massimiliano Berretta | Q64819590 |
| P2093 | author name string | Massimo Libra | |
| | Diana Crivellari | |
| | Marcello De Cicco | |
| | Petar Stefanovski | |
| | Andrea Freschi | |
| | Luca Balestreri | |
| | Enzo Galligioni | |
| | Roberto Sorio | |
| | Angela Buonadonna | |
| | Alberto Merlo | |
| | Rachele Volpe | |
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| | A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma | Q33374365 |
| | Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer | Q34262346 |
| | Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | Q34723863 |
| | Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes | Q36346529 |
| | Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study | Q40765720 |
| | Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. | Q41773666 |
| | The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. | Q42607185 |
| | Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines | Q47584438 |
| | Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation | Q64038880 |
| | A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone | Q68815180 |
| | Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer | Q68815187 |
| | Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma | Q71067347 |
| | Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU | Q71807292 |
| | Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients | Q73713708 |
| | Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response | Q77317862 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncology | Q162555 |
| | renal cell carcinoma | Q1164529 |
| | metastatic renal cell carcinoma | Q19000948 |
| P304 | page(s) | 400-404 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Tumori | Q15757838 |
| P1476 | title | Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution | |
| | Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution | |
| P478 | volume | 89 | |